$ABSI

Absci Corp

No enriched coverage for $ABSI in the last 7 days.

No SEC Form 4 filings for $ABSI in the last 30 days.

Low

Absci (NASDAQ:ABSI) Stock Price Up 11% - Still a Buy?

Absci (NASDAQ:ABSI) shares rose 11% on Friday, despite missing quarterly earnings and revenue expectations significantly. The company operates with a negative net margin and analysts forecast a negative EPS for the fiscal year, leading to a consensus "Hold" rating with an average price target of $6.44. Insider ownership is 10.49% (including a recent purchase by Andreas Busch) and institutional ownership is approximately 52%.

Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Several prominent stocks are projected to open lower in Wednesday's pre-market session. Absci Corp (NASDAQ: ABSI) is down after reporting lower-than-expected quarterly sales, while DigitalOcean Holdings Inc (NYSE: DOCN) declined following a $700 million offering announcement. Other companies experiencing pre-market dips include Intrepid Potash Inc (NYSE: IPI), Pacira Biosciences Inc (NASDAQ: PCRX), Velo3D Inc (NASDAQ: VELO), Sasol Ltd (NYSE: SSL), CF Industries Holdings, Inc. (NYSE: CF), and Venture Global Inc (NASDAQ: VG).

Absci to Participate in Upcoming Investor Conferences

Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company utilizing generative AI for therapeutic development, announced its participation in four upcoming investor conferences in March 2026. The company will engage in fireside chats and host one-on-one meetings with investors at events including the TD Cowen 46th Annual Health Care Conference and Leerink Partners 2026 Global Healthcare Conference. Webcasts of the fireside chats will be available on Absci's investor relations website.